BC
AEGR

Birchview Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

Birchview Capital’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-46,000
Closed -$626K – 44
2015
Q3 		$626K Hold
46,000
– – 0.4% 21
2015
Q2 		$873K Hold
46,000
– – 0.46% 18
2015
Q1 		$1.2M Buy
+46,000
New +$1.17M 0.63% 13

Other funds holding AEGR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Birchview Capital's AEGR Position: Q4 2015 in Review

Birchview Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 46,000 shares — an estimated $626K sold.

Birchview Capital first reported a position in AEGR in Q1 2015 and held it in 3 quarters. The position peaked at $1.2M in Q1 2015. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

  • Birchview Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Birchview Capital sold 46,000 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $626K.
  • Birchview Capital first reported a position in Aegerion Pharmaceuticals in Q1 2015 and held it in 3 quarters.
  • Birchview Capital's Aegerion Pharmaceuticals position peaked at $1.2M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on Birchview Capital's 13F filing for Q4 2015, filed 8 Feb 2016.